o	Nykode Therapeutics has reached the enrollment target of 50 patients in its VB
C-02 trial for the treatment of advanced cervical cancer
o	Interim efficacy and safety data expected in 1H 2022


Oslo, Norway, February 11, 2022 - Nykode Therapeutics AS (Euronext Growth
(Oslo): NYKD), a clinical-stage biopharmaceutical company dedicated to the
discovery and development of vaccines and novel immunotherapies, today announced
the completion of patient enrollment in the Phase 2 study of VB10.16, Nykode's
lead cancer vaccine candidate, in combination with Roche's checkpoint inhibitor
atezolizumab for the treatment of advanced cervical cancer. VB10.16 is a
potentially first-in-class off-the-shelf therapeutic HPV16 cancer vaccine
designed to induce strong HPV16 specific T cell responses for the treatment of
HPV16-positive cancers. 

"We are pleased to report the completion of patient enrollment in our ongoing
Phase 2 trial of VB10.16, our wholly owned product candidate for the treatment
of cervical cancer," said Michael Engsig, CEO of Nykode Therapeutics. "This is
an important inflection point for Nykode as we advance our lead candidate
through the clinic. After successfully enrolling 50 patients across trial sites
in six countries, we look forward to reporting interim efficacy and safety data
from the first patients in the first half of 2022. In parallel, we are exploring
the possibility of evaluating VB10.16 in other HPV-driven cancers, including
head and neck cancer." 
 
VB C-02 is a multi-center, open-label Phase 2 trial of patients with advanced or
recurrent, non-resectable HPV16-positive cervical cancer. Almost 20 European
sites in six European countries were engaged in enrolling patients in the trial.
Nykode has previously reported positive interim safety data from the trial.

Siri Torhaug, Chief Medical Officer of Nykode Therapeutics, commented: "Cervical
cancer is a leading cause of death for women. It is an indication which
continues to have a high unmet medical need with limited response to standard of
care treatment in an advanced setting. We are very happy to have reached this
important milestone for our lead cancer vaccine VB10.16 and look forward to
continuing the development program. We are thankful for the patients, their
families, the investigators and the trial site personnel who have made this
trial possible." 

Additional information about the Phase 2 trial is available at
clinicaltrials.gov (NCT04405349).


Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to
the discovery and development of vaccines and novel immunotherapies for the
treatment of cancer and infectious diseases. Nykode's modular vaccine technology
specifically targets antigens to Antigen Presenting Cells, which are essential
for inducing rapid, strong and long-lasting antigen specific immune responses
and eliciting efficacious clinical responses. 

Nykode's lead product candidates are VB10.16, a therapeutic vaccine for the
treatment of human papilloma virus 16 induced malignancies which is in Phase 2
for the treatment of cervical cancer